Lance Lizi Xia (Dr.)
About Lance Lizi Xia (Dr.)
Dr. Lance Lizi Xia is a Senior Principal Investigator at BeiGene in Beijing, China, with extensive experience in drug discovery and assay development.
Company
Dr. Lance Lizi Xia currently works at BeiGene as a Senior Principal Investigator. BeiGene is a biotechnology company headquartered in Beijing, China, focusing on molecular and translational research to develop innovative cancer therapies. He is based in the Changping District and works onsite.
Title
Dr. Lance Lizi Xia holds the title of Senior Principal Investigator at BeiGene. His responsibilities include developing and validating robust biophysical and biochemical assays and building a Fragment-Based Drug Discovery (FBDD) platform to support 'First-in-class' programs.
Education and Expertise
Dr. Lance Lizi Xia has an extensive academic background. He earned his Ph.D. in Molecular Pharmacology, Medicinal, and Pharmaceutical Chemistry from Leiden University from 2013 to 2018. Prior to his Ph.D., he achieved a Master's degree in Bio-Pharmaceutical Sciences from the same university between 2011 and 2013. Before moving to the Netherlands, he studied at Chengdu Institute of Biology under the Chinese Academy of Sciences, where he earned a Master's degree in Natural Product Chemistry/Medicinal Chemistry from 2006 to 2009.
Professional Background
Dr. Lance Lizi Xia has a diverse professional background that spans multiple roles and geographic regions. From 2021 to 2023, he served as Scientist & Project Leader at ZoBio in Leiden, South Holland. He also worked at ZoBio as a Scientist-Assay Specialist from 2018 to 2023. His earlier roles included a Doctoral Researcher position at Universiteit Leiden from 2013 to 2018, and a Co-founder and Vice President of Marketing & Sales at Orange Essentials in 2012-2013. Additionally, he has experience working as a Chemist at Shanghai Chempartner in Chengdu, China, and as a Research Assistant at Chengdu Institute of Biology.
Achievements and Contributions
Dr. Lance Lizi Xia has made significant contributions in the field of drug discovery. At BeiGene, he developed an FBDD platform to support 'First-in-class' programs and designed an HTS (High Throughput Screening) library for 'an ideal one-million' compounds. Additionally, he designed complete HTS automation workflows capable of testing 200,000 compounds per day. He has played a crucial role in proposing new modalities and targets to initiate new programs and collaborating with cross-functional teams to advance drug discovery from hit identification to preclinical development.